Interpace

IDXG NASDAQ
0.7134
-0.0037
-0.52%
盘后: 0.7170 +0.0036 +0.50% 16:31 05/17 EDT
开盘
0.7065
昨收
0.7171
最高
0.7270
最低
0.6950
成交量
29.47万
成交均量(3M)
28.91万
52周最高
1.780
52周最低
0.6729
换手率
0.77%
市值
2,717.77万
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供Interpace IDXG股票价格,Interpace股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.
展开 >

最近浏览

名称
价格
涨跌幅